Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.56 |
| ▸ | CD63 | P08962 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551918 | 0.87 | SYK (0.69) | SYKCD63JAK2 | |
| SCHEMBL14916360 | 0.84 | CCND3 (0.46) | SYK | |
| SCHEMBL14917135 | 0.82 | HTR2C (0.56) | SYK | |
| SCHEMBL14916894 | 0.81 | SYK (0.46) | SYKCD63 | |
| SCHEMBL15551877 | 0.80 | SYK (0.57) | SYKCD63JAK2 | |
| SCHEMBL15551875 | 0.80 | SYK (0.57) | SYKCD63JAK2 | |
| SCHEMBL14916917 | 0.79 | SYK (0.49) | SYKCD63JAK2 | |
| SCHEMBL28564010 | 0.78 | SYK (0.69) | SYKCD63JAK2 | |
| SCHEMBL16851493 | 0.76 | SYK (0.71) | SYKCD63JAK2 | |
| SCHEMBL14927017 | 0.76 | WNT3A (0.46) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773640-B1 | BICYCLIC PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2773640-B1 | BICYCLIC PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2773640-A1 | BICYCLIC PIPERAZINE COMPOUNDS | Hoffmann-La Roche AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8722676-B2 | Bicyclic piperazine compounds | GENENTECH, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013067260-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116262-A1 | BICYCLIC PIPERAZINE COMPOUNDS | BTK, LCK, SYK | SYK 3/4885CD63 4572/4885JAK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.